Prednisolone 5 mg JENAPHARM ( DrugBank: Prednisolone )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
41	Giant cell arteritis	1

41. Giant cell arteritis

---

Clinical trials : 128 /  Drugs : 139 - (DrugBank : 36) / Drug target genes : 33 - Drug target pathways : 124

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2017-003978-13-FR (EUCTR)	22/08/2019	19/04/2019	A safety and efficacy study of ABT-494 in subjects with Giant Cell Arteritis.	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Upadacitinib in Subjects with Giant Cell Arteritis: Select-GCA	Giant Cell Arteritis MedDRA version: 20.0;Level: LLT;Classification code 10018250;Term: Giant cell arteritis;System Organ Class: 100000004866;Therapeutic area: Diseases [C] - Immune System Diseases [C20]	Product Name: Upadacitinib Product Code: ABT-494 INN or Proposed INN: Upadacitinib Product Name: Upadacitinib Product Code: ABT-494 INN or Proposed INN: Upadacitinib Trade Name: Prednisolon 1 mg JENAPHARM Product Name: Prednisolone INN or Proposed INN: PREDNISOLONE Other descriptive name: PREDNISOLONE Trade Name: Prednisolon 1 mg JENAPHARM Product Name: Prednisolone INN or Proposed INN: PREDNISOLONE Other descriptive name: PREDNISOLONE Trade Name: Prednisolon 5 mg JENAPHARM Product Name: Prednisolone INN or Proposed INN: PREDNISOLONE Other descriptive name: PREDNISOLONE Trade Name: Prednisolone 5 mg JENAPHARM Product Name: Prednisolone INN or Proposed INN: PREDNISOLONE Other descriptive name: PREDNISOLONE	AbbVie Deutschland GmbH & Co. KG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	420	Phase 3	United States;Portugal;Greece;Spain;Austria;Russian Federation;France;Hungary;Canada;Australia;Denmark;Netherlands;Germany;Japan;New Zealand